The nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $7.88 billion in 2025 to $8.84 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to increasing use of radioactive tracers in diagnostics, expansion of hospital-based nuclear medicine units, rising demand for functional imaging, availability of technetium-based radiopharmaceuticals, growth of clinical research in nuclear medicine.
The nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $13.77 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to increasing investments in theranostics, rising adoption of precision oncology diagnostics, expansion of PET imaging infrastructure, growing focus on targeted radiopharmaceutical development, increasing regulatory support for nuclear diagnostics. Major trends in the forecast period include increasing adoption of pet-based diagnostic radiopharmaceuticals, rising demand for personalized nuclear diagnostics, growing integration of imaging and therapeutic applications, expansion of oncology-focused nuclear medicine procedures, enhanced focus on short-half-life radiotracers.
The growing incidence of cancer is anticipated to drive the expansion of the nuclear medicine diagnostics market in the coming years. Cancer refers to a group of diseases marked by the uncontrolled growth and spread of abnormal cells, which may form tumors within the body. The increasing prevalence of cancer is largely attributed to the aging global population, as cancer risk rises significantly with age, along with advances in healthcare that are extending life expectancy. Nuclear medicine diagnostics plays a critical role in the detection, staging, and monitoring of multiple cancer types by using radioactive substances that can be identified by specialized imaging systems to generate detailed images of organ structure and function. For example, in May 2025, data from the National Cancer Institute indicated that in 2022 nearly 20 million people worldwide were diagnosed with cancer and 9.7 million deaths were recorded, with projections estimating an increase to 33 million new cases and 18.2 million cancer-related deaths annually by 2050. As a result, the rising burden of cancer is contributing significantly to the growth of the nuclear medicine diagnostics market.
Leading companies operating in the nuclear medicine diagnostics market are increasingly focused on launching advanced medical solutions to strengthen their competitive positioning. Advanced medical technologies refer to innovative tools and systems designed to enhance patient outcomes, elevate standards of care, and support improved health management. For instance, in August 2023, Gleneagles Hospital, a Malaysia-based healthcare services provider, announced the launch of a dedicated Nuclear Medicine Unit. This unit is a specialized hospital facility equipped with state-of-the-art technology and supported by trained professionals, enabling early detection, accurate diagnosis, and treatment of diseases through nuclear medicine imaging techniques.
In March 2025, GE HealthCare Technologies, Inc., a United States-based medical technology and pharmaceutical company, acquired Nihon Medi Physics Co., Ltd. for an undisclosed consideration. Through this acquisition, GE HealthCare seeks to incorporate Nihon Medi Physics’ strong capabilities in radiopharmaceutical development and manufacturing, thereby enhancing its ability to supply next-generation molecular imaging agents across neurology, cardiology, and oncology applications. Nihon Medi Physics Co., Ltd. is a Japan-based radiopharmaceutical company specializing in the development and supply of radioactive pharmaceuticals used in diagnostic nuclear medicine procedures.
Major companies operating in the nuclear medicine diagnostics market are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Theragnostics Ltd., Eczacıbaşı-Monrol Nuclear Products Co.
North America was the largest region in the nuclear medicine diagnostics market in 2025. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the nuclear medicine diagnostics market by increasing costs of imported radioisotopes, cyclotron components, imaging accessories, and specialized handling equipment. Diagnostic centers and hospitals in North America and Europe are most affected due to reliance on imported radiopharmaceutical inputs, while Asia-Pacific faces higher production and export costs. These tariffs are raising diagnostic procedure costs and affecting supply chain reliability. However, they are also encouraging domestic radioisotope production, regional supply chain strengthening, and investment in local radiopharmaceutical manufacturing capabilities.
The nuclear medicine diagnostics market research report is one of a series of new reports that provides nuclear medicine diagnostics market statistics, including nuclear medicine diagnostics industry global market size, regional shares, competitors with a nuclear medicine diagnostics market share, detailed nuclear medicine diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine diagnostics industry. This nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Nuclear medicine employs radioactive substances administered internally to diagnose illnesses or selectively target and eliminate diseased or damaged organs and tissues during treatment. This field encompasses the utilization of radioactive drugs for research, therapeutic, and diagnostic objectives. In diagnostic nuclear medicine, radioactive tracers are employed to visualize and/or measure the overall or localized function of specific organs, providing valuable insights for medical diagnosis and treatment planning.
The primary categories of nuclear medicine diagnostics encompass SPECT radiopharmaceuticals and PET radiopharmaceuticals. SPECT Radiopharmaceuticals, or single-photon emission computerized tomography, pertain to gamma-ray tomographic imaging techniques employed in the field of nuclear medicine. These methods find application in diverse medical areas such as cardiology, thyroid, neurology, oncology, among others. End-users of these diagnostic technologies include hospitals, diagnostic centers, and research institutes.
The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $13.77 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to increasing investments in theranostics, rising adoption of precision oncology diagnostics, expansion of PET imaging infrastructure, growing focus on targeted radiopharmaceutical development, increasing regulatory support for nuclear diagnostics. Major trends in the forecast period include increasing adoption of pet-based diagnostic radiopharmaceuticals, rising demand for personalized nuclear diagnostics, growing integration of imaging and therapeutic applications, expansion of oncology-focused nuclear medicine procedures, enhanced focus on short-half-life radiotracers.
The growing incidence of cancer is anticipated to drive the expansion of the nuclear medicine diagnostics market in the coming years. Cancer refers to a group of diseases marked by the uncontrolled growth and spread of abnormal cells, which may form tumors within the body. The increasing prevalence of cancer is largely attributed to the aging global population, as cancer risk rises significantly with age, along with advances in healthcare that are extending life expectancy. Nuclear medicine diagnostics plays a critical role in the detection, staging, and monitoring of multiple cancer types by using radioactive substances that can be identified by specialized imaging systems to generate detailed images of organ structure and function. For example, in May 2025, data from the National Cancer Institute indicated that in 2022 nearly 20 million people worldwide were diagnosed with cancer and 9.7 million deaths were recorded, with projections estimating an increase to 33 million new cases and 18.2 million cancer-related deaths annually by 2050. As a result, the rising burden of cancer is contributing significantly to the growth of the nuclear medicine diagnostics market.
Leading companies operating in the nuclear medicine diagnostics market are increasingly focused on launching advanced medical solutions to strengthen their competitive positioning. Advanced medical technologies refer to innovative tools and systems designed to enhance patient outcomes, elevate standards of care, and support improved health management. For instance, in August 2023, Gleneagles Hospital, a Malaysia-based healthcare services provider, announced the launch of a dedicated Nuclear Medicine Unit. This unit is a specialized hospital facility equipped with state-of-the-art technology and supported by trained professionals, enabling early detection, accurate diagnosis, and treatment of diseases through nuclear medicine imaging techniques.
In March 2025, GE HealthCare Technologies, Inc., a United States-based medical technology and pharmaceutical company, acquired Nihon Medi Physics Co., Ltd. for an undisclosed consideration. Through this acquisition, GE HealthCare seeks to incorporate Nihon Medi Physics’ strong capabilities in radiopharmaceutical development and manufacturing, thereby enhancing its ability to supply next-generation molecular imaging agents across neurology, cardiology, and oncology applications. Nihon Medi Physics Co., Ltd. is a Japan-based radiopharmaceutical company specializing in the development and supply of radioactive pharmaceuticals used in diagnostic nuclear medicine procedures.
Major companies operating in the nuclear medicine diagnostics market are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Theragnostics Ltd., Eczacıbaşı-Monrol Nuclear Products Co.
North America was the largest region in the nuclear medicine diagnostics market in 2025. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the nuclear medicine diagnostics market by increasing costs of imported radioisotopes, cyclotron components, imaging accessories, and specialized handling equipment. Diagnostic centers and hospitals in North America and Europe are most affected due to reliance on imported radiopharmaceutical inputs, while Asia-Pacific faces higher production and export costs. These tariffs are raising diagnostic procedure costs and affecting supply chain reliability. However, they are also encouraging domestic radioisotope production, regional supply chain strengthening, and investment in local radiopharmaceutical manufacturing capabilities.
The nuclear medicine diagnostics market research report is one of a series of new reports that provides nuclear medicine diagnostics market statistics, including nuclear medicine diagnostics industry global market size, regional shares, competitors with a nuclear medicine diagnostics market share, detailed nuclear medicine diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine diagnostics industry. This nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Nuclear medicine employs radioactive substances administered internally to diagnose illnesses or selectively target and eliminate diseased or damaged organs and tissues during treatment. This field encompasses the utilization of radioactive drugs for research, therapeutic, and diagnostic objectives. In diagnostic nuclear medicine, radioactive tracers are employed to visualize and/or measure the overall or localized function of specific organs, providing valuable insights for medical diagnosis and treatment planning.
The primary categories of nuclear medicine diagnostics encompass SPECT radiopharmaceuticals and PET radiopharmaceuticals. SPECT Radiopharmaceuticals, or single-photon emission computerized tomography, pertain to gamma-ray tomographic imaging techniques employed in the field of nuclear medicine. These methods find application in diverse medical areas such as cardiology, thyroid, neurology, oncology, among others. End-users of these diagnostic technologies include hospitals, diagnostic centers, and research institutes.
The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Nuclear Medicine Diagnostics Market Characteristics
3. Nuclear Medicine Diagnostics Market Supply Chain Analysis
4. Global Nuclear Medicine Diagnostics Market Trends and Strategies
5. Nuclear Medicine Diagnostics Market Analysis of End Use Industries
7. Global Nuclear Medicine Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Nuclear Medicine Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Nuclear Medicine Diagnostics Market Segmentation
10. Nuclear Medicine Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Nuclear Medicine Diagnostics Market
12. China Nuclear Medicine Diagnostics Market
13. India Nuclear Medicine Diagnostics Market
14. Japan Nuclear Medicine Diagnostics Market
15. Australia Nuclear Medicine Diagnostics Market
16. Indonesia Nuclear Medicine Diagnostics Market
17. South Korea Nuclear Medicine Diagnostics Market
18. Taiwan Nuclear Medicine Diagnostics Market
19. South East Asia Nuclear Medicine Diagnostics Market
20. Western Europe Nuclear Medicine Diagnostics Market
21. UK Nuclear Medicine Diagnostics Market
22. Germany Nuclear Medicine Diagnostics Market
23. France Nuclear Medicine Diagnostics Market
24. Italy Nuclear Medicine Diagnostics Market
25. Spain Nuclear Medicine Diagnostics Market
26. Eastern Europe Nuclear Medicine Diagnostics Market
27. Russia Nuclear Medicine Diagnostics Market
28. North America Nuclear Medicine Diagnostics Market
29. USA Nuclear Medicine Diagnostics Market
30. Canada Nuclear Medicine Diagnostics Market
31. South America Nuclear Medicine Diagnostics Market
32. Brazil Nuclear Medicine Diagnostics Market
33. Middle East Nuclear Medicine Diagnostics Market
34. Africa Nuclear Medicine Diagnostics Market
36. Nuclear Medicine Diagnostics Market Competitive Landscape and Company Profiles
37. Nuclear Medicine Diagnostics Market Other Major and Innovative Companies
40. Nuclear Medicine Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Nuclear Medicine Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for nuclear medicine diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nuclear medicine diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: SPECT Radiopharmaceuticals; PET Radiopharmaceuticals2) By Application: Cardiology; Thyroid; Neurology; Oncology; Other Applications
3) By End-User: Hospitals And Diagnostic Centers; Research Institutes
Subsegments:
1) By SPECT Radiopharmaceuticals: Technetium-99m-Based Radiopharmaceuticals; Iodine-123-Based Radiopharmaceuticals; Thallium-201-Based Radiopharmaceuticals; Other SPECT Radiopharmaceuticals2) By PET Radiopharmaceuticals: Fluorine-18-Based Radiopharmaceuticals; Carbon-11-Based Radiopharmaceuticals; Gallium-68-Based Radiopharmaceuticals; Other PET Radiopharmaceuticals
Companies Mentioned: Siemens AG; Bayer Aktiengesellschaft; Novartis AG; GE Healthcare Technologies Inc.; Perkin Elmer Inc.; Mallinckrodt Pharmaceuticals; Bracco Diagnostics Inc.; Lantheus Holdings Inc.; IBA Radiopharma Solutions; Curium SAS; Eckert & Ziegler Strahlen- und Medizintechnik AG; Advanced Accelerator Applications; Telix Pharmaceuticals Limited; Nordion (Canada) Inc.; NorthStar Medical Technologies LLC; SHINE Medical Technologies LLC; Navidea Biopharmaceuticals Inc.; Cyclopharm Limited; Isologic Innovative Radiopharmaceuticals; Clarity Pharmaceuticals Limited; Actinium Pharmaceuticals Inc.; Jubilant DraxImage Inc.; PharmaLogic Holdings Corp; Institute of Isotopes Co Ltd.; Theragnostics Ltd.; Eczacıbaşı-Monrol Nuclear Products Co.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Nuclear Medicine Diagnostics market report include:- Siemens AG
- Bayer Aktiengesellschaft
- Novartis AG
- GE Healthcare Technologies Inc.
- Perkin Elmer Inc.
- Mallinckrodt Pharmaceuticals
- Bracco Diagnostics Inc.
- Lantheus Holdings Inc.
- IBA Radiopharma Solutions
- Curium SAS
- Eckert & Ziegler Strahlen- und Medizintechnik AG
- Advanced Accelerator Applications
- Telix Pharmaceuticals Limited
- Nordion (Canada) Inc.
- NorthStar Medical Technologies LLC
- SHINE Medical Technologies LLC
- Navidea Biopharmaceuticals Inc.
- Cyclopharm Limited
- Isologic Innovative Radiopharmaceuticals
- Clarity Pharmaceuticals Limited
- Actinium Pharmaceuticals Inc.
- Jubilant DraxImage Inc.
- PharmaLogic Holdings Corp
- Institute of Isotopes Co Ltd.
- Theragnostics Ltd.
- Eczacıbaşı-Monrol Nuclear Products Co.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 8.84 Billion |
| Forecasted Market Value ( USD | $ 13.77 Billion |
| Compound Annual Growth Rate | 11.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
